{
  "meta": {
    "title": "Monoclonal_Antibodies",
    "url": "https://brainandscalpel.vercel.app/monoclonal-antibodies-b2e55151.html",
    "scrapedAt": "2025-11-29T18:33:31.277Z"
  },
  "questions": [
    {
      "id": 10910,
      "choices": [
        {
          "id": 43606,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adamantinoma</span></span></span></p>"
        },
        {
          "id": 43607,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basal cell Ca</span></span></span></p>"
        },
        {
          "id": 43608,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colorectal Ca</span></span></span></p>"
        },
        {
          "id": 43609,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Crohn&rsquo;s disease</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cetuximab is used for treatment of?</span></span></span></p>",
      "unique_key": "Q6649761",
      "question_audio": null,
      "question_video": null,
      "map_id": 36488,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Colorectal Ca</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Cetuximab</strong> is a <strong>monoclonal antibody</strong> that targets the <strong>epidermal growth factor receptor (EGFR)</strong>, which is <strong>overexpressed</strong> in many <strong>types of cancers</strong>, including a <strong>significant proportion of colorectal cancers</strong>. By<strong> binding to EGFR, cetuximab inhibits</strong> the <strong>receptor&#39;s</strong> <strong>function</strong>, which is to <strong>trigger pathways</strong> that lead to<strong> cell growth and proliferation</strong>. This <strong>inhibition</strong> helps<strong> to control the growth </strong>of <strong>cancer cells, </strong>making <strong>cetuximab an effective treatment</strong> for<strong> colorectal cancer, </strong>particularly in <strong>tumors</strong> that express <strong>high levels of EGFR.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adamantinoma:</span></strong><span style=\"font-size:12.0pt\"> This is a<strong> rare</strong> type of<strong> tumor</strong> that typically<strong> arises in the bones,</strong> specifically the <strong>tibia and the jawbone.</strong> <strong>Cetuximab</strong> is<strong> not</strong> indicated for the<strong> treatment of adamantinoma.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Basal cell Ca (Carcinoma):</span></strong><span style=\"font-size:12.0pt\"> Basal cell carcinoma is primarily<strong> treated</strong> with <strong>surgical methods, topical treatments, </strong>or <strong>radiation</strong> <strong>therapy.</strong> <strong>Cetuximab</strong> is<strong> not</strong> used for <strong>basal cell carcinoma</strong> as it generally <strong>does not </strong>express<strong> EGFR </strong>to a significant extent.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Crohn&rsquo;s disease:</span></strong><span style=\"font-size:12.0pt\"> This is an <strong>inflammatory bowel disease</strong>; treatment typically involves <strong>immunosuppressive </strong>and <strong>anti-inflammatory agents</strong> such as <strong>TNF&alpha; inhibitors (e.g., infliximab). Cetuximab</strong> has <strong>no</strong> role in the <strong>treatment of Crohn&#39;s disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">MONOCLONAL ANTIBODIES</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-130406.png\" style=\"height:713px; width:1000px\" /></span></strong></span></span></p>",
      "correct_choice_id": 43608,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10911,
      "choices": [
        {
          "id": 43610,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avelumab</span></span></span></p>"
        },
        {
          "id": 43611,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atezolizumab</span></span></span></p>"
        },
        {
          "id": 43612,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cetuximab</span></span></span></p>"
        },
        {
          "id": 43613,
          "text": "<p style=\"margin-right:-1px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Durvalumab</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All the following are PD-L1 inhibitors except?</span></span></span></p>",
      "unique_key": "Q7237449",
      "question_audio": null,
      "question_video": null,
      "map_id": 36489,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Cetuximab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Cetuximab </strong>is a<strong> monoclonal antibody </strong>that specifically targets the <strong>epidermal growth factor receptor (EGFR) </strong>on the <strong>surface of cancer</strong> <strong>cells.</strong> It functions by<strong> inhibiting EGFR</strong> and its<strong> associated signaling pathways</strong>, which are often <strong>upregulated in various types of cancers,</strong> particularly<strong> colorectal and head and neck cancers</strong>. This mechanism is <strong>distinct from the mode of action of PD-L1 inhibitors</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/402.jpg\" style=\"height:333px; width:500px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Avelumab:</span></strong><span style=\"font-size:12.0pt\"> Avelumab is a <strong>PD-L1 inhibitor </strong>that <strong>blocks the interaction between PD-L1 on tumor cells </strong>and<strong> PD-1 on T cells.</strong> By doing so, it<strong> prevents </strong>the<strong> tumor</strong> from evading the<strong> immune response, enabling the immune system </strong>to attack the <strong>cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Atezolizumab:</span></strong><span style=\"font-size:12.0pt\"> Similar to<strong> Avelumab,</strong> Atezolizumab is a<strong> monoclonal antibody </strong>that binds to <strong>PD-L1,</strong> <strong>inhibiting </strong>its <strong>interaction</strong> with<strong> PD-1</strong>. This <strong>blockade </strong>enhances the<strong> body&#39;s immune response against tumor cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Durvalumab:</span></strong><span style=\"font-size:12.0pt\"> Durvalumab also<strong> targets PD-L1</strong>, <strong>preventing</strong> it from <strong>binding to PD-1.</strong> It is part of the<strong> group of immune</strong> <strong>checkpoint inhibitors</strong> that help to<strong> activate the immune system against cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While <strong>Avelumab, Atezolizumab, and Durvalumab </strong>are <strong>all PD-L1 inhibitors</strong> enhancing the<strong> immune system&#39;s ability to fight cancer,</strong> <strong>Cetuximab</strong> works through a<strong> different mechanism </strong>by <strong>targeting EGFR on cancer cells</strong>.&nbsp;</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Immune Check Point inhibitors</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-131641.png\" style=\"height:247px; width:1000px\" /></p>",
      "correct_choice_id": 43612,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10900,
      "choices": [
        {
          "id": 43566,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a chimeric monoclonal antibody against CD-20</span></span></span></p>"
        },
        {
          "id": 43567,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It has dose dependent kinetics</span></span></span></p>"
        },
        {
          "id": 43568,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is used for treatment of non- Hodgkin lymphoma</span></span></span></p>"
        },
        {
          "id": 43569,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Its most common adverse effect is infusion related reactions</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following statements about rituximab is false? </span></span></span></p>",
      "unique_key": "Q3931391",
      "question_audio": null,
      "question_video": null,
      "map_id": 36484,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) It has dose dependent kinetics.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rituximab</strong> is <strong>chimeric monoclonal antibody </strong>against <strong>CD-20 B-cells. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rituximab</strong> follows<strong> first order kinetics.</strong> Its<strong> clearance</strong> remains<strong> constant irrespective of plasma concentration. Dose-dependent kinetics</strong> means <strong>zero-order kinetics</strong> i.e. <strong>clearance and t1/2 change</strong> with <strong>dose (plasma concentration).</strong> Drugs following<strong> zero-order kinetics</strong> are <strong>warfarin, alcohol, high dose aspirin, tolbutamide, theophylline and phenytoin. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Infusion-related </strong>reactions are seen in approximately<strong> 50% </strong>of patients receiving<strong> first infusion</strong>. The <strong>incidence decreases</strong> with <strong>subsequent infusions.</strong> Starting with <strong>low doses </strong>and <strong>pre-treatment</strong> with <strong>steroids or anti-histaminic </strong>are the <strong>methods</strong> to <strong>reduce infusion related reactions. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rituximab</strong> may cause <strong>reactivation of hepatitis B;</strong> therefore, patients should be <strong>screened for hepatitis B</strong> before <strong>initiation</strong> of therapy. It rarely<strong> causes reactivation of JC virus </strong>leading to <strong>progressive multifocal leukoencephalopathy. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rituximab </strong>can be<strong> used for treatment</strong> of </span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-Hodgkin lymphoma </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mantle cell lymphoma </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic lymphocytic leukemia </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Auto-immune hemolytic anemia </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diffuse large B cell lymphoma. </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rheumatoid arthritis </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. It is a chimeric monoclonal antibody against CD-20:</span></strong><span style=\"font-size:12.0pt\"> This statement is <strong>true</strong> and accurately describes the <strong>biological target </strong>of<strong> rituximab,</strong> essential for<strong> its efficacy in treating diseases</strong> like<strong> lymphomas </strong>where<strong> CD-20 positive B-cells are pathologically active.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. It is used for treatment of non-Hodgkin lymphoma:</span></strong><span style=\"font-size:12.0pt\"> <strong>True. Rituximab </strong>is extensively<strong> used in</strong> the treatment of <strong>non-Hodgkin</strong> <strong>lymphoma</strong> among other<strong> lymphoid malignancies, </strong>leveraging its ability to target<strong> CD-20 </strong>for<strong> therapeutic effect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Its most common adverse effect is infusion related reactions:</span></strong><span style=\"font-size:12.0pt\"> Also <strong>true</strong>.<strong> Infusion-related reactions</strong> occur in about<strong> half of</strong> <strong>all patients </strong>during the <strong>first infusion of rituximab,</strong> though the <strong>risk decreases</strong> with <strong>subsequent treatments.</strong> <strong>Pre-medicating </strong>with <strong>steroids or antihistamines </strong>can<strong> mitigate</strong> these reactions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rituximab,</strong> a <strong>chimeric monoclonal antibody</strong> targeting CD-20 B-cells, is <strong>primarily used </strong>to treat various<strong> hematological malignancies</strong> and some <strong>autoimmune conditions</strong>. Its <strong>pharmacokinetics does not</strong> follow<strong> dose-dependent kinetics </strong>but instead<strong> exhibits first-order</strong> <strong>kinetics,</strong> meaning its<strong> clearance remains constant </strong>across<strong> different plasma concentrations.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In<strong> contrast,</strong> <strong>dose-dependent kinetics (zero-order kinetics) </strong>describes a scenario where the<strong> drug&rsquo;s clearance rate and half-life </strong>change with<strong> varying doses</strong>, which is<strong> not</strong> the case with <strong>rituximab</strong>. This <strong>differentiates rituximab </strong>from drugs like <strong>warfarin and phenytoin</strong>, which follow<strong> zero-order kinetics</strong> at <strong>therapeutic or higher doses.</strong></span></span></span></p>",
      "correct_choice_id": 43567,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10902,
      "choices": [
        {
          "id": 43574,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is an antibody produced entirely from mice containing no human component</span></span></span></p>"
        },
        {
          "id": 43575,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a monoclonal antibody produced by injecting the HER2 antigen</span></span></span></p>"
        },
        {
          "id": 43576,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a polyclonal antibody</span></span></span></p>"
        },
        {
          "id": 43577,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a monoclonal antibody containing only human components</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 56-year-old female presents with breast carcinoma, and she was prescribed Herceptin (trastuzumab). Which of the following statements regarding this drug is true?</span></span></span></p>",
      "unique_key": "Q9739289",
      "question_audio": null,
      "question_video": null,
      "map_id": 36485,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) It is a monoclonal antibody produced by injecting the HER2 antigen</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Herceptin (trastuzumab)</strong> is a <strong>monoclonal antibody</strong> that specifically targets the<strong> human epidermal growth factor receptor</strong> <strong>2 (HER2) protein</strong>, which is <strong>overexpressed </strong>in approximately <strong>25% of breast cancers</strong>. It is produced by <strong>injecting</strong><strong> </strong>the <strong>HER2 antigen</strong> into<strong> mice </strong>and then<strong> harvesting the resulting monoclonal antibodies.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>It is an antibody produced entirely from mice containing no human component:</strong> This statement is <strong>incorrect.</strong> <strong>Trastuzumab</strong> is<strong> not</strong> a<strong> fully murine </strong>(<strong>mouse-derived</strong>) <strong>antibody.</strong> It is, in fact, a<strong> humanized monoclonal antibody, </strong>which means it is<strong> predominantly of</strong> <strong>human origin</strong>, but with <strong>mouse-derived antigen-binding regions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option C. It is a polyclonal antibody:</strong> This statement is<strong> incorrect. Trastuzumab</strong> is a <strong>monoclonal antibody,</strong> meaning it is made by <strong>identical immune cells</strong> that are all<strong> clones</strong> of a <strong>unique parent cell</strong>, and it <strong>targets a specific epitope</strong> on the <strong>HER2 receptor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>It is a monoclonal antibody containing only human components: </strong>This is <strong>not accurate</strong>. <strong>Trastuzumab </strong>is <strong>humanized,</strong> meaning it <strong>combines both human and mouse antibody components.</strong> The <strong>majority</strong> of the<strong> antibody is human,</strong> with <strong>mouse</strong> <strong>components</strong> in the<strong> antigen-binding region.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Trastuzumab (Herceptin)</strong> is a<strong> humanized monoclonal antibody </strong>used in the treatment of <strong>HER2-positive breast cancer.</strong> It is crucial to understand that it<strong> targets the HER2 receptor,</strong> which is <strong>overexpressed </strong>in certain <strong>aggressive forms of breast cancer</strong>, helping to<strong> inhibit</strong> the <strong>growth and&nbsp;</strong></span></span><strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">spread of cancer cells. </span></span></span></strong></p>",
      "correct_choice_id": 43575,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10914,
      "choices": [
        {
          "id": 43622,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxorubicin</span></span></span></p>"
        },
        {
          "id": 43623,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carboplatin</span></span></span></p>"
        },
        {
          "id": 43624,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate</span></span></span></p>"
        },
        {
          "id": 43625,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cetuximab</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient with head and neck cancer was given radiotherapy. After 6 months of radiotherapy, chemotherapy was started but patient presented with the clinical picture as shown after start of chemotherapy. What is the likely drug responsible for this?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/405.jpg\" style=\"height:271px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q3399549",
      "question_audio": null,
      "question_video": null,
      "map_id": 36481,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Doxorubicin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical picture shows <strong>&lsquo;radiation recall syndrome&rsquo;</strong>. The <strong>causative agent is Doxorubicin</strong>.</span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Radiation recall syndrome (RRS)</strong> is characterized by an <strong>acute inflammatory reaction</strong> in previously<strong> irradiated</strong> <strong>areas of the body,</strong> usually <strong>occurring within days to weeks</strong> of <strong>administration of anticancer drugs.</strong> The hallmark of <strong>RRS is erythema</strong>, which can <strong>progress to blistering, ulceration, and desquamation.</strong></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The<strong> exact </strong>cause of<strong> RRS</strong> is<strong> not well understood,</strong> but it is thought to be related to an <strong>interaction between</strong> the <strong>chemotherapy drugs </strong>and the <strong>radiation therapy.</strong> <strong>Radiation therapy can</strong> cause<strong> damage to the DNA of cells</strong> in the<strong> target area,</strong> and this <strong>damage can persist </strong>for some time. <strong>If chemotherapy</strong> is<strong> administered </strong>after<strong> radiation</strong> <strong>therapy,</strong> it may <strong>interact</strong> with this <strong>residual radiation damage, triggering an inflammatory response</strong> in the <strong>previously irradiated tissue</strong> and causing the symptoms of <strong>RRS.</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Carboplatin:</span></strong><span style=\"font-size:12.0pt\"> While <strong>Carboplatin</strong> can have a <strong>variety of side effects,</strong> it is <strong>less </strong>commonly associated with <strong>radiation recall</strong> <strong>syndrome.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Methotrexate:</span></strong><span style=\"font-size:12.0pt\"><strong> Methotrexate</strong> can cause<strong> mucositis and skin reactions </strong>but is<strong> not </strong>typically associated with<strong> radiation recall.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cetuximab:</span></strong><span style=\"font-size:12.0pt\"> <strong>Cetuximab</strong>, a <strong>monoclonal antibody targeting EGFR,</strong> is associated with <strong>skin reactions;</strong> however, it is <strong>not</strong> <strong>typically</strong> cited as a<strong> cause of radiation recall syndrome.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>most common drugs</strong> associated with<strong> RRS are anthracyclines</strong> (such a<strong>s doxorubicin</strong>), <strong>taxanes</strong> (such as <strong>paclitaxel</strong>), and <strong>gemcitabine. </strong></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 43622,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10923,
      "choices": [
        {
          "id": 43658,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pembrolizumab </span></span></span></p>"
        },
        {
          "id": 43659,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Trastuzumab</span></span></span></p>"
        },
        {
          "id": 43660,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab</span></span></span></p>"
        },
        {
          "id": 43661,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ocrelizumab</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monoclonal antibody used in Head and Neck cancer is? </span></span></span></p>",
      "unique_key": "Q5847493",
      "question_audio": null,
      "question_video": null,
      "map_id": 36482,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Pembrolizumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Pembrolizumab</strong>: Pembrolizumab is a <strong>monoclonal antibody</strong> that targets the <strong>programmed death 1 (PD-1) receptor on T</strong> <strong>cells</strong>, which helps to <strong>stimulate</strong> an<strong> immune response against cancer cells.</strong> This therapy has been approved by the <strong>FDA to</strong> <strong>treat head and neck cancer, </strong>as well as other types of cancer such as <strong>melanoma, non-small cell lung cancer, and Hodgkin lymphoma.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> <strong>Trastuzumab</strong>: Trastuzumab is a<strong> monoclonal antibody</strong> that is <strong>used</strong> to treat <strong>HER2-positive breast cancer, </strong>which is a type of <strong>breast cancer</strong> that has <strong>high levels of the protein HER2</strong> on the<strong> surface</strong> of the <strong>cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Rituximab</strong>: Rituximab is a<strong> monoclonal antibody</strong> that is used to treat non-Hodgkin&#39;s lymphoma, <strong>chronic lymphocytic</strong> <strong>leukemia, and rheumatoid arthritis</strong>. It works by <strong>targeting a protein </strong>called <strong>CD20 </strong>on the <strong>surface of B cells</strong>, which are a type of <strong>immune cell </strong>that can become<strong> cancerous </strong>in certain conditions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Ocrelizumab</strong>: Ocrelizumab is a <strong>monoclonal antibody</strong> that is<strong> used to treat multiple sclerosis, a chronic autoimmune disease</strong> that affects the<strong> central nervous system</strong>. It<strong> targets a protein</strong> called<strong> CD20 on B cells,</strong> which are thought to play a role in the <strong>development of the disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Pembrolizumab </strong>is utilized in the treatment of<strong> head and neck cancer </strong>due to its ability to <strong>enhance </strong>the <strong>immune response </strong>against <strong>cancer cells by inhibiting the PD-1 pathway</strong>. This action <strong>helps to counteract the immune evasion tactics </strong>employed by many <strong>cancers,</strong> <strong>highlighting </strong>the importance of<strong> immune checkpoint inhibitors</strong> in <strong>modern oncology.</strong></span></span></span></p>",
      "correct_choice_id": 43658,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10925,
      "choices": [
        {
          "id": 43666,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ustekinumab</span></span></span></p>"
        },
        {
          "id": 43667,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brodalumab</span></span></span></p>"
        },
        {
          "id": 43668,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Secukinumab</span></span></span></p>"
        },
        {
          "id": 43669,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sarilumab</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All are monoclonal antibodies approved for use in psoriasis, Except:</span></span></span></p>",
      "unique_key": "Q9284368",
      "question_audio": null,
      "question_video": null,
      "map_id": 36483,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Sarilumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>monoclonal antibodies</strong> approved for use in <strong>psoriasis</strong> are <strong>Ustekinumab, Brodalumab, and Secukinumab.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Sarilumab</strong> is a<strong> monoclonal antibody</strong> that targets the<strong> interleukin-6 (IL-6) receptor</strong> and is approved for the treatment of <strong>rheumatoid arthritis,</strong> but it is<strong> not </strong>approved for use in<strong> psoriasis.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ustekinumab:</span></strong><span style=\"font-size:12.0pt\"> This <strong>monoclonal antibody </strong>targets both <strong>interleukin-12 (IL-12) and interleukin-23 (IL-23).</strong> It is approved for the treatment of<strong> psoriasis, psoriatic arthritis, and Crohn&#39;s disease.</strong> It works by<strong> modulating the immune response </strong>that contributes to the<strong> inflammation</strong> characteristic of these conditions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Brodalumab:</span></strong><span style=\"font-size:12.0pt\"> <strong>Targets</strong> the<strong> interleukin-17 (IL-17) receptor,</strong> approved for the treatment of<strong> psoriasis.</strong> By <strong>blocking IL-17,</strong> <strong>Brodalumab</strong> helps <strong>reduce inflammation </strong>and the<strong> rapid skin cell </strong>turnover associated with <strong>psoriasis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Secukinumab:</span></strong><span style=\"font-size:12.0pt\"> This <strong>antibody targets interleukin-17A (IL-17A) </strong>and is approved for <strong>psoriasis, psoriatic arthritis,</strong> and <strong>ankylosing spondylitis</strong>. It works similarly to<strong> Brodalumab </strong>by targeting a key<strong> cytokine</strong> involved in<strong> inflammatory processes</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While<strong> Ustekinumab, Brodalumab, and Secukinumab</strong> are <strong>approved </strong>and <strong>effective </strong>treatments for<strong> psoriasis</strong> through their<strong> targeting </strong>of <strong>specific interleukins</strong> involved in <strong>inflammatory pathways,</strong> <strong>Sarilumab,</strong> though a <strong>monoclonal antibody</strong>, is <strong>not</strong> used for <strong>psoriasis</strong> as it <strong>targets IL-6</strong>, <strong>relevant primarily</strong> in the context of<strong> rheumatoid arthritis. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Monoclonal antibodies for psoriasis:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-150951.png\" style=\"height:541px; width:700px\" /></span></strong></span></span></p>",
      "correct_choice_id": 43669,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10938,
      "choices": [
        {
          "id": 43718,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Alemtuzumab</span></span></span></p>"
        },
        {
          "id": 43719,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ocrelizumab</span></span></span></p>"
        },
        {
          "id": 43720,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Natalizumab</span></span></span></p>"
        },
        {
          "id": 43721,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pertuzumab</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is a US-FDA approved anti-CD 20 monoclonal antibody for primary progressive multiple sclerosis? </span></span></span></p>",
      "unique_key": "Q5768620",
      "question_audio": null,
      "question_video": null,
      "map_id": 36487,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. B) Ocrelizumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ocrelizumab</strong> is an <strong>anti-CD20 monoclonal antibody </strong>approved by the <strong>US-FDA</strong> for the<strong> treatment of primary progressive</strong> <strong>multiple sclerosis (PPMS),</strong> as well as for<strong> relapsing forms of multiple sclerosis (RMS)</strong>. Its <strong>mechanism of action </strong>involves binding to<strong> CD20-positive B cells</strong>, which play a significant role in the <strong>inflammatory process of multiple sclerosis.</strong> By <strong>depleting these B cells, ocrelizumab reduces the inflammatory activity</strong> and can <strong>slow the progression of the disease.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Alemtuzumab:</span></strong><span style=\"font-size:12.0pt\"> Alemtuzumab<strong> targets CD52</strong>, a<strong> protein </strong>expressed on the <strong>surface of T and B lymphocytes</strong>, and is <strong>used in </strong>the treatment of <strong>relapsing-remitting multiple sclerosis,</strong> but not for PPMS.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Natalizumab:</span></strong><span style=\"font-size:12.0pt\"> Natalizumab <strong>targets integrin alpha-4</strong>, involved in the<strong> migration of leukocytes across the blood-brain barrier.</strong> It is <strong>used</strong> for <strong>relapsing forms of multiple sclerosis</strong> and not indicated for PPMS.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pertuzumab:</span></strong><span style=\"font-size:12.0pt\"> Pertuzumab is a<strong> monoclonal antibody </strong>that <strong>targets the HER2 receptor,</strong> which is <strong>overexpressed in HER2-positive breast cancer.</strong> It is <strong>not</strong> used in the<strong> treatment of multiple sclerosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ocrelizumab </strong>is the<strong> first and only US-FDA </strong>approved therapy specifically indicated for <strong>primary progressive multiple sclerosis.</strong></span></span></span></p>",
      "correct_choice_id": 43719,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10936,
      "choices": [
        {
          "id": 43710,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hodgkin&rsquo;s lymphoma</span></span></span></p>"
        },
        {
          "id": 43711,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Medulloblastoma</span></span></span></p>"
        },
        {
          "id": 43712,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Retinoblastoma</span></span></span></p>"
        },
        {
          "id": 43713,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Endometrial carcinoma</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nivolumab is used in the treatment of?</span></span></span></p>",
      "unique_key": "Q8755280",
      "question_audio": null,
      "question_video": null,
      "map_id": 36486,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Hodgkin&rsquo;s lymphoma</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Nivolumab</span></strong><span style=\"font-size:12.0pt\"> is a<strong> checkpoint inhibitor</strong> that targets the <strong>PD-1 (programmed cell death protein 1) on T cells</strong>. It is<strong> used</strong> in the treatment of <strong>various cancers, including Hodgkin&rsquo;s lymphoma.</strong> <strong>Nivolumab </strong>works by <strong>blocking PD-1, enhancing the immune system&#39;s response</strong> <strong>against cancer cells. </strong>It has been particularly <strong>effective</strong> in treating <strong>classical Hodgkin&#39;s lymphoma,</strong> especially in<strong> cases </strong>that are <strong>refractory</strong> to<strong> other treatments.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Medulloblastoma:</span></strong><span style=\"font-size:12.0pt\"><strong> Not</strong> a primary indication for <strong>nivolumab.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Retinoblastoma:</span></strong><span style=\"font-size:12.0pt\"> <strong>Not</strong> treated with <strong>nivolumab.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Endometrial carcinoma:</span></strong><span style=\"font-size:12.0pt\"> <strong>Pembrolizumab</strong> is more commonly associated with <strong>endometrial carcinoma, not nivolumab.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Important<strong> indications</strong> of <strong>Immune Check Point Inhibitors</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/416.jpg\" style=\"height:742px; width:1000px\" /></span></span></span></p>",
      "correct_choice_id": 43710,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}